The activating interplay of thrombosis and inflammation (thromboinflammation) has been
established as a major underlying pathway, driving not only cardiovascular disease but also …

Increasing evidence indicates that inflammation can cause thrombosis by a von Willebrand
factor (VWF)-mediated mechanism that includes endothelial activation, secretion of VWF …

Atherosclerosis underlies most cardiovascular diseases, and is accepted as a primary cause
of mortality worldwide. Proteases have been implicated in the development and progression …

Pathogenesis of thrombotic thrombocytopenic purpura (TTP) was a mystery for over half a
century until the discovery of ADAMTS13. ADAMTS13 is primarily synthesized in the liver …

ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13)
has antithrombotic properties because it cleaves von Willebrand factor (VWF) in smaller …

Summary ADAMTS‐13, a plasma reprolysin‐like metalloprotease, cleaves von W illebrand
factor (VWF). Severe deficiency of plasma ADAMTS‐13 activity results in thrombotic …

Abstract Von Willebrand Factor (VWF) plays an important role in hemostasis by mediating
platelet adhesion and aggregation. Ultralarge VWF multimers are cleaved by ADAMTS13 in …

The role of platelet adhesion, activation, and aggregation in acute atherothrombotic events
such as myocardial infarction and stroke is well established. There is increasing evidence …

With timely and effective treatment, most patients with thrombotic thrombocytopenic purpura
(TTP) survive the acute TTP episode. In addition to the risk of relapse, TTP survivors have …

The third-generation tyrosine kinase inhibitor (TKI) ponatinib has been associated with high
rates of acute ischemic events. The pathophysiology responsible for these events is …